We are thrilled to announce that we’ve been awarded U.S. Patent No. 12,595,460 B2, for the Method and Apparatus for Producing CAR-T Cells. The newly issued patent reinforces our innovation mission in cell therapy manufacturing and supports the company’s GoFast workflow for rapid, cost-effective CAR-T production. The patent covers methods and the instrument for producing CAR-T cells in a closed fluidic system using MARS Atlas, integrating key manufacturing steps including cell isolation, incubation/transduction, and harvesting. The patented workflow includes a flexible platform architecture designed to streamline CAR-T manufacturing.
This milestone marks an important step in our mission to enable cost-effective, faster, simpler, and more scalable advanced therapy manufacturing. By supporting a more integrated manufacturing workflow, the patented technology is designed to help reduce operational complexity and shorten production timelines for autologous cell therapies.
“Receiving this patent is an important validation of the innovation behind our GoFast CAR-T manufacturing approach,” said Yuchen Zhou, our CEO. “We believe the future of CAR-T cell therapy strongly and dedicate to delivering CAR-T manufacturing platforms that are faster, more practical, more cost-effective, and easily expandable to applications beyond oncology. This patent strengthens our foundation as we continue advancing solutions that can help bring transformative CAR-T therapies to patients worldwide.”
Applied Cells will be showcasing the GoFast platform and related capabilities at ASGCT 2026. Please visit Poster #2398 and Booth #932, where attendees can learn more about GoFast CAR-T manufacturing workflows. For more information about Applied Cells and our MARS platforms enabled with GoFast CAR-T, visit link.
Kat Ginda-Mäkelä
